Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)

摘要

Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.
原文英語
頁(從 - 到)S785-S788
期刊Journal of Cancer Research and Therapeutics
14
發行號10
DOIs
出版狀態已發佈 - 一月 1 2018

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

指紋 深入研究「Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan」主題。共同形成了獨特的指紋。

引用此